PPARG and periodontitis: Hassumi et al. showed that the well-known PPAR-γ agonist rosiglitazone may be able to reduce alveolar bone loss in ligature-induced periodontitis in a rat model, by decreasing RANKL expression and inhibiting osteoclast differentiation [39].